Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VVOS Vivos Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VVOS
Price (delayed)
$2.42
Market cap
$14.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.73
Enterprise value
$13.31M
Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that
Highlights
VVOS's EPS has soared by 84% YoY and by 22% from the previous quarter
The net income has grown by 28% YoY
The company's quick ratio has surged by 67% YoY but it has shrunk by 51% QoQ
Vivos Therapeutics's revenue has increased by 9% YoY but it has decreased by 2.7% from the previous quarter
The equity has declined by 45% since the previous quarter
The company's gross margin fell by 2.2% QoQ
Key stats
What are the main financial stats of VVOS
Market
Valuations
Earnings
Shares outstanding
5.89M
Market cap
$14.25M
Enterprise value
$13.31M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.23
Price to sales (P/S)
1.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.91
Revenue
$14.63M
Gross profit
$8.59M
Operating income
-$11.31M
Net income
-$11.24M
EBIT
-$11.24M
EBITDA
-$10.63M
Free cash flow
-$14.51M
Per share
Balance sheet
Liquidity
EPS
-$1.73
EPS diluted
-$1.73
Free cash flow per share
-$1.69
Book value per share
$0.75
Revenue per share
$1.7
TBVPS
$0.94
Total assets
$11.28M
Total liabilities
$6.88M
Debt
$1.4M
Equity
$4.41M
Working capital
-$1.09M
Debt to equity
0.32
Current ratio
0.77
Quick ratio
0.65
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
-72.6%
Gross margin
58.7%
Net margin
-76.8%
Operating margin
-77.3%
Return on assets
-77.8%
Return on equity
-170.4%
Return on invested capital
-566.7%
Return on capital employed
-170.7%
Return on sales
-76.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VVOS stock price
How has the Vivos Therapeutics stock price performed over time
Intraday
-2.81%
1 week
6.14%
1 month
-14.79%
1 year
24.1%
YTD
-43.59%
QTD
-15.09%
Financial performance
How have Vivos Therapeutics's revenue and profit performed over time
Revenue
$14.63M
Gross profit
$8.59M
Operating income
-$11.31M
Net income
-$11.24M
Gross margin
58.7%
Net margin
-76.8%
The company's operating margin rose by 36% YoY but it fell by 4% QoQ
Vivos Therapeutics's net margin has increased by 34% YoY but it has decreased by 3.6% from the previous quarter
Vivos Therapeutics's operating income has increased by 30% YoY
The net income has grown by 28% YoY
Price vs fundamentals
How does VVOS's price correlate with its fundamentals
Growth
What is Vivos Therapeutics's growth rate over time
Valuation
What is Vivos Therapeutics stock price valuation
P/E
N/A
P/B
3.23
P/S
1.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.91
VVOS's EPS has soared by 84% YoY and by 22% from the previous quarter
The price to book (P/B) is 75% lower than the 5-year quarterly average of 12.9 but 47% higher than the last 4 quarters average of 2.2
The equity has declined by 45% since the previous quarter
VVOS's P/S is 43% below its 5-year quarterly average of 2.5 but 18% above its last 4 quarters average of 1.2
Vivos Therapeutics's revenue has increased by 9% YoY but it has decreased by 2.7% from the previous quarter
Efficiency
How efficient is Vivos Therapeutics business performance
The company's return on equity has surged by 91% YoY and by 14% QoQ
The return on invested capital has surged by 86% year-on-year and by 33% since the previous quarter
The company's return on assets rose by 42% YoY
VVOS's ROS is up by 34% YoY but it is down by 3.6% from the previous quarter
Dividends
What is VVOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VVOS.
Financial health
How did Vivos Therapeutics financials performed over time
VVOS's total assets is 64% higher than its total liabilities
The current ratio has surged by 71% year-on-year but it has declined by 49% since the previous quarter
The company's quick ratio has surged by 67% YoY but it has shrunk by 51% QoQ
Vivos Therapeutics's debt is 68% less than its equity
VVOS's debt to equity has dropped by 90% year-on-year but it has surged by 68% since the previous quarter
The equity has declined by 45% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.